Successful results of a University of Liverpool-led trial that utilised nanotechnology to improve drug therapies for HIV patients has been presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, a leading annual conference of HIV research, clinical practice and progress.
21 February 2017 | University of Liverpool press release
The tiny implantable drug pump is being developed by Intarcia Therapeutics Inc. It can hold six or 12 months’ supply of medicine and is designed to deliver microdoses continuously to patients, ensuring they stay on the treatment.
30 December 2016 | Wall Street Journal
By Election Day Nov. 8, after an eventful primary season and a noxious election cycle, it seemed that most HIV advocates were ready to get to work with a soon-to-be President-elect Hillary Clinton's soon-to-be administration, to continue the pioneering work activists forged under President Obama in addressing HIV in the U.S. Then the unthinkable happened. In the wee hours of Nov. 9, Donald J. Trump was declared the president-elect of the United States.
21 November 2016 | The Body
How many doses of Truvada-based PrEP (pre-exposure prophylaxis) are needed to provide adequate protection against HIV? Might it be possible to take PrEP only before and after sex—instead of every day?
12 September 2016 | BETA blog
A smartphone application developed by the University of Liverpool to help healthcare professionals to safely prescribe medications for HIV patients has won an international award.
01 September 2016 | University of Liverpool press release
Women need daily doses of the antiviral medication Truvada to prevent HIV infection while men only need two doses per week due to the way the drug accumulates in different body tissues, according to a new study from pharmacy researchers the University of North Carolina at Chapel Hill.
04 March 2016 | Eurekalert Medicine & Health
The latest study appears to show a different type of "sanctuary," as the researchers called it, harboring cells with low levels of HIV replication that move into the blood. This suggests that virus growth could occur in a place where drug concentrations are very low.
28 January 2016 | Washington Post
Many patients taking direct acting antivirals (DAA) to treat hepatitis C virus (HCV) are at risk of clinically significant drug-drug interactions (DDIs), new research shows.
23 December 2015 | Medscape (requires free registration)
Through the Positive Persons' Forum and other initiatives, many people with HIV in Scotland have made it clear that they are very concerned about growing older with HIV. We have set out some of these concerns in the infographic below (or view it as a plain online image). The top 5 concerns were confidentiality, the effects of HIV medication, drug interactions, Financial stability and ignorance and stigma.
12 August 2015 | HIV Scotland-
The tool is known as a PAD (Paper Analytical Device) and is essentially a mini lab on a piece of card, Mercy explains. "It's simple, you apply the tablet on a specific area on the device, dip the card in water and wait for a colour reaction, then compare the results to a standard to interpret the results." Each of the cards contains 12 separate strips which react with a drug to create a "coloured bar code" that gives information about its chemical content.
08 June 2015 | BBC Health